Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018.

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

Pasadena. CA | Posted on January 25th, 2019

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3194897.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3194897.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Appreciating the classical elegance of time crystals: Physicists at ETH Zurich have developed a versatile framework for studying periodically driven systems, providing a unifying platform to explore so-called 'time crystals' in both the classical and the quantum regime September 20th, 2019

'Nanochains' could increase battery capacity, cut charging time September 20th, 2019

SMART announces a revolutionary tech to study cell nanomechanics: New research discovery enables scientists to study membrane mechanics of cell's nucleus, revolutionising the understanding of metastatic cancers as well as opening the doors for identification of stem cells for the September 20th, 2019

Nano bulb lights novel path: Rice University engineers create tunable, nanoscale, incandescent light source September 20th, 2019

Nanomedicine

SMART announces a revolutionary tech to study cell nanomechanics: New research discovery enables scientists to study membrane mechanics of cell's nucleus, revolutionising the understanding of metastatic cancers as well as opening the doors for identification of stem cells for the September 20th, 2019

Tiny bubbles in our body could fight cancer better than chemo September 18th, 2019

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia September 18th, 2019

New health monitors are flexible, transparent and graphene enabled September 13th, 2019

Announcements

Appreciating the classical elegance of time crystals: Physicists at ETH Zurich have developed a versatile framework for studying periodically driven systems, providing a unifying platform to explore so-called 'time crystals' in both the classical and the quantum regime September 20th, 2019

'Nanochains' could increase battery capacity, cut charging time September 20th, 2019

SMART announces a revolutionary tech to study cell nanomechanics: New research discovery enables scientists to study membrane mechanics of cell's nucleus, revolutionising the understanding of metastatic cancers as well as opening the doors for identification of stem cells for the September 20th, 2019

Nano bulb lights novel path: Rice University engineers create tunable, nanoscale, incandescent light source September 20th, 2019

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results July 25th, 2019

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.76 as of March 31, 2019; an Increase of 4.5% From December 31, 2018 May 1st, 2019

180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019 April 26th, 2019

Events/Classes

The future of materials with graphene nanotubes starts in Japan September 19th, 2019

Scientists invented how to improve steel properties by 100 times: A breakthrough method of ion implantation makes stainless steel more wear resistant by 100 times September 6th, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences August 30th, 2019

Nanoparticles could someday give humans built-in night vision August 28th, 2019

Nanobiotechnology

Tiny bubbles in our body could fight cancer better than chemo September 18th, 2019

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia September 18th, 2019

Scientists create a nanomaterial that is both twisted and untwisted at the same time: The material developed at University of Bath allows for incredibly sensitive detection of the direction molecules twist September 13th, 2019

Inspired by natural signals in living cells, researchers design artificial gas detector: Tiny box puts itself together and glows September 13th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project